Tema Oncology ETF·Financial Services

Tema Oncology ETF receives a Hold rating due to inconsistent returns but it does currently have a high Quant Ranking in the healthcare subclass. CANC offers diversified exposure across market caps and geographies, focusing on firms combating cancer through biotech, pharmaceuticals, diagnostics, and devices. The ETF holds 55 stocks, with top 10 comprising 40% of the portfolio, balancing established giants and innovative small-caps.

NEW YORK--(BUSINESS WIRE)--Tema ETFs (“Tema”), a leader in institutional-quality and actively managed exchange-traded funds, today announced the appointment of Steve Munroe as President. In this role, Mr. Munroe will partner with Tema Founder and CEO Maurits Pot and the firm's leadership team to accelerate the company's next phase of growth. He will oversee branding, marketing, distribution, and product strategy as Tema continues to gain momentum—raising more than $1 billion in net new assets o.

Thrivent Financial for Lutherans cut its holdings in shares of Tema Oncology ETF (NASDAQ: CANC) by 84.6% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 147,472 shares of the company's stock after selling 810,003 shares during the period. Thrivent Financial
The Tema Oncology ETF (CANC) seeks to invest in companies that potentially stand to benefit from further advances in oncology related biotechnology and healthcare.
Financial Services
Asset Management
2023-08-14
0.91
Market Peers





